Vice President, Research, Health Policy & Abuse Liability, Pinney Associates Inc and Professor, Behavioral Biology
Johns Hopkins Univ School of Medicine Prediction & Treatment Unit, National Inst on Drug Abuse Intramural Research Program
Jack E. Henningfield, PhD is Vice President, Research, Health Policy and Abuse Liability, Pinney Associates and Adjunct Professor of Behavioral Biology, Part Time, Departement of Psychiatry and Behavioral Sciences, The Johns Hopkins Univ School of Medicine. Dr. Henningfield was trained in abuse potential assessment and related sciences in the Psychopharmacology Program at the Univ of Minnesota and the Behavioral Biology Program of The Johns Hopkins Univ in the 1970s. At the National Inst on Drug Abuse (NIDA), which contributes to Controlled Substances Act drug scheduling, he served as Chief of Clinical Pharmacology and Abuse Potential Assessment and contributed to NIDA's drug scheduling recommendations to the US Food & Drug Administration (FDA) and Drud Enforcement Administration in his capacity as the Chief of the Biology of Dependence and Abuse Potential Assessment Section. In 1996, he joined Pinney Associates to consult on these issues, and broader public health and policy matters. Dr. Henningfield has published more than 500 articles, books, and governmental reports related to CNS acting drugs and tobacco products, as well as dietary supplements such as kratom. He contributed to abuse potential assessment monographs from NIDA in the 1980s, FDA's first draft guidance in 1990 and to expert reviews and conferences on abuse potential involving FDA in the 2000s leading to FDA's 2015 Abuse Deterrent Opioid Guidance and 2017 Assessment of Abuse Potential of Drugs Guidance. He has received awards for his public health contributions from the World Health Organization, American Society of Addiction Medicine, College on Problems of Drug Dependence, US Dept of Health and Human Services and other organizations. At Pinney Associates, his focus is on abuse potential, Controlled Substances Act 8-factor drug scheduling, international drug scheduling, abuse deterrent formulation assessments, drug labeling and risk management.
Monday, September 11, 2023
8:00 AM – 9:30 AM PT
Disclosure(s): Pinney Associates: Consultant/Advisory Board (), Employment ()
2 - The Current Regulatory 8-Factor Analysis & Its Use in Substance Abuse Liability
Monday, September 11, 2023
8:00 AM – 9:30 AM PT
Disclosure(s): Pinney Associates: Consultant/Advisory Board (), Employment ()